Type 1 Diabetes Mellitus - Heat Map and Analysis

ReportsWorldwide has announced the addition of a new report title Type 1 Diabetes Mellitus - Heat Map and Analysis to its growing collection of premium market research reports.

Type I diabetes mellitus (T1DM) is a metabolic disease characterized by chronic hyperglycemia, and is caused by defective insulin secretion by pancreatic beta cells. Under normal circumstances these cells would secrete insulin into the blood stream, which facilitates the uptake of glucose by target cells for metabolism, subsequently lowering blood glucose levels.

The disease typically has childhood onset and patients cannot survive without pharmacotherapy, which has historically consisted of multiple subcutaneous administrations of insulin analogs per day. Furthermore, the disease is associated with organ failure and diabetic ketoacidosis, which are both potentially fatal side-effects. The disease therefore represents a significant burden and daily inconvenience for patients.

Scope of the Report:

- How is the T1DM market landscape expected to evolve with the repositioning of currently successful products and the advent of promising novel pipeline products?

- What are the clinical characteristics of currently approved therapies for T1DM, in terms of specific safety and efficacy parameters?

- How are clinical safety and efficacy parameters linked to the key unmet needs in this indication?

- How will new therapeutic forms affect the market for currently successful recombinant peptides, and are they able to yield comparable clinical efficacy results to currently favored therapies?

- In a market dominated by recombinant peptides, do small molecule therapies have sufficient differentiating characteristics to have a strong impact?

- How will the repositioning of currently successful T2DM therapies affect the competitive landscape?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6866

Reasons to buy

- Understand the current clinical landscape by considering the treatment options available for each patient segment.

- Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.

- Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.

- Understand the relative strengths and weaknesses of the studies used to gather these data.

- Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.

- Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/type-1-diabetes-mellitus-heat-map-and-analysis

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.